ARCHIVES

Phase III Trial Would Give Clearer Picture of C225 Role

This article is from The Cancer Letter archive.

Vol. 28 No. | March 8, 2002

Download PDF Visit The Full Archive

Related Articles

Weak Structure, Deficiencies, Cited In Dana-Farber Reviews

November 3, 1995

In Brief: O’Conor Now Top Prospect If Rauscher Leaves; Flood Gives NCI Increase Of Only $11 Million

May 14, 1976

Group trials need prioritization, review, NCI official says.

July 25, 2003

DCT Board Approves Phase 2/3 Studies Of LAK-IL-2

February 14, 1986

NCI Grant Funding Up $74 Million; Centers, Groups also Receive Funding Boost

March 8, 1996

In Brief: Cowan to Direct Eppley Cancer Center; Nealon Retires From NCI Liaison Office

June 11, 1999